### \*\*\*\*\*Published January 2019\*\*\* MarketVIEW: mRNA vaccines (infectious diseases) (CAT: VAMV079)

Product Name	:	MarketVIEW: mRNA vaccines (infectious diseases)
Description	:	mMRNA vaccines: landscape overview and pipeline analysis
Contents	:	Executive presentation (120 slides, .pdf) + 1 MS Excel workbook (.xls)
Therapeutic Area	:	Novel vaccine technologies
Publication date	:	January 2019
Catalogue No	:	VAMV079

# Background

'Nucleic acid-based therapeutics', based on mRNA, are a group of technologies with potential applications in vaccination for cancer, infectious diseases and diseases requiring protein replacement therapy. Improvements in mRNA formulation and delivery using lipid nanoparticle and cationic nanoparticle encapsulation have overcome early issues with stability and complex dendritic cell (DC) loading techniques. Landmark studies have shown that directly injected encapsulated mRNA is both safe and immunogenic triggering humoral and cellular immune responses in healthy and cancer patients.

mRNA vaccines are potentially disruptive because they provide some critical advantages over existing vaccine antigen approaches.

This MarketVIEW product consists of a detailed Executive presentation (~120 .pdf slides) and MS-Excel workbook (.xls) which gives a comprehensive overview of mRNA technologies and their potential application in the prophylatic and therapeutic setting for cancer and infectious diseases indications. An R&D pipeline analysis is provided which details all current mRNA candidates at clinical stages. Major companies and alliances are outlined with a focus on each individual program (infectious diseases). Importantly, drawing upon our VacZine Analytics research portfolio, a strategic analysis is included whereby opportunities associated with mRNA technologies are contrasted with the competitive threat level should a new vaccine progress to licensure. This report is ideal for any client wishes to understand the potential significance of this emerging field.

## Bringing life to vaccine strategy...


### www.vaczine-analytics.com

# Methodology

**VacZine Analytics** has closely monitored all significant source material pertaining to mRNA vaccines technologies, vaccine development and competitive environment. Source materials used are literature articles, government websites, medical bodies and associations, conference proceedings, news articles, expert comment etc.

### PRODUCT CONTENTS: Published January 2019 (CAT No: VAMV079)

\*\*\*\*This product is composed of one Excel workbook (.xls)<sup>1</sup> and an Executive presentation (.pdf)<sup>2</sup>



Slide number = 120 (.pdf) Model worksheet number 5 (.xls) Bibliography ~ 140 references

<sup>2</sup> Presentation titles may apply to more than one slide (.pdf form only)

## Bringing life to vaccine strategy...



<sup>&</sup>lt;sup>1</sup> Workbook contents available on request (.xls)



#### **PRODUCT COST:**

VacZine Analytics will grant a [enter region] license to [enter client name], for the price of:

FULL PRODUCT (All deliverables) - USD \$8,995/ GBP £7,000<sup>#</sup> (region license)\*


# Indicative company rate only. Prevailing rate applied to date of transaction.
\*A region is North America, Europe or ROW
For orders in the UK, VAT at 20.0% will be added to final invoice total Biotech and "not for profit" rates are available upon request

#### HOW TO ORDER:

To order please contact your region account manager or order direct at <u>orders@vaczine-analytics.com</u> This report can also be purchased online. Please review the **TERMS and CONDITIONS** of purchase.



Bringing life to vaccine strategy...



#### **TERMS and CONDITIONS:**

VacZine Analytics – a trading division of Assay Advantage Ltd UK Company Number: 5807728 (Herein referred to as "The Company"). (Herein [enter client name] to as "The Client").

- 1. All Rights Reserved. This finished research product is a licensed product. It may not be reproduced, stored in a retrieval system or transmitted in any form without the written permission of the Company **VacZine Analytics** (a division of Assay Advantage Ltd).
- 2. The license granted by the Company to the Client will be non-exclusive, non-transferable and should only be used for the Client business purposes at the agreed Client sites/location in accordance with this agreement. The Client will have no ownership rights over the research product.
- 3. Invoicing will 100% after submission of the deliverables (.pdf) and (.xls) to the Client.
- 4. If not purchased online invoices are payable within thirty days of the invoice date.
- 5. All proposals are quoted in \$USD dollars, or £GBP or €euro and invoices are to be settled in the same currency.
- 6. The Company agrees not to disclose to any third party confidential information acquired in the course of providing the research product listed without the prior written consent of the Client. Exception occurs when the information is already in the public domain or when disclosure is necessary to help the Company's employees, and agents with the performance of the Company's obligations to achieve satisfactory completion of the project and approved in writing by the Client.
- 7. Force Majeure: The Company will not be liable for any delay or failure to perform any obligation under this Agreement insofar as the performance of such obligation is prevented by an event beyond our reasonable control, included by not limited to, earthquake, fire, flood or any other natural disaster, labour dispute, riot, revolution, terrorism, acts of restraint of government or regulatory authorities, failure of computer equipment and failure or delay of sources from which data is obtained.
- 8. Please also refer to Master TERMS and CONDITIONS available upon request.

#### VacZine Analytics

a division of Assay Advantage Ltd Warren House Bells Hill Bishops Stortford Herts CM23 2NN United Kingdom Tel: +44 (0) 1279 813155 E-mail: info@vacZine-analytics.com

### Bringing life to vaccine strategy...

## www.vaczine-analytics.com



## **About VacZine Analytics:**

**VacZine Analytics** is an established strategic research agency based in the United Kingdom. Its aim is to provide disease and commercial analysis for the vaccine industry and help build the case for developing new vaccines and biologics.

For more information, please visit our website www.vacZine-analytics.com

VacZine Analytics (R) is a trading division of Assay Advantage Ltd, UK Company Number: 5807728 VacZine Analytics (R) and "the spiral logo" are UK Registered Trademarks, 2009

## Bringing life to vaccine strategy...

